In 2021, the patient began experiencing shortness of breath while moving between floors in her home and was subsequently diagnosed with Autoimmune Idiopathic Interstitial Lung Disease. The prescribed antirejection medication, CellCept, did not arrest her progression. Seeking alternative treatment, the patient initiated molecular hydrogen inhalation on January 1, 2024. Remarkably, her shortness of breath significantly improved within 10 days, and by January 21, 2024, she could ascend stairs without encountering respiratory difficulties. A follow-up CT scan on February 1, 2024, revealed persistent Scleroderma, a chronic hardening of connective tissue. Despite this, the patient has chosen to continue with a regimen of hydrogen inhalation, acupuncture, and Chinese herbal medicine. The plan includes a repeat CT scan in three months to monitor progress. 在2021年，患者在家中樓層間行走時開始出現呼吸急促的症狀，隨後被診斷為自身免疫性特發性間質性肺病。所開具的抗排斥藥物CellCept 並未阻止其病情的進展。為尋求替代治療，患者於2024年1月1日開始進行分子氫吸入療法。令人驚訝的是，她的呼吸急促在10天內顯著改善，到了2024年1月21日，她能夠上樓梯而無需面對呼吸困難。於2024年2月1日進行的隨訪CT掃描顯示患者仍然存在硬皮症，即結締組織慢性硬化。儘管如此，患者選擇繼續進行分子氫吸入療法、針灸和中草藥治療。計劃包括在三個月後進行重複CT掃描以監測病情進展。
